Abstract Objective To study the expression of the Fra-1 gene in the peripheral blood of children with Wilms tumor and its clinical significance. Methods Fifty children pathologically diagnosed with Wilms tumor between December 2012 and January 2018 were enrolled as the case group, and 40 healthy children for physical examination were selected as the control group. Among the 45 children with Wilms tumor who were followed up, the children with continuous remission were included in the ideal efficacy group (n=33), and those with recurrence, metastasis or death were included in the poor efficacy group (n=12). Peripheral blood samples were collected from all subjects. Quantitative real-time PCR was used to measure the mRNA expression of Fra-1. Results The case group had significantly higher mRNA expression of Fra-1 in peripheral blood than the control group (P < 0.05). In the case group, Fra-1 mRNA expression was significantly different between the individuals with and without distant metastasis and those with different TNM stages (P < 0.05), but was not significantly different between the individuals with different sexes, ages, tumor diabetes, tumor locations and alpha-fetoprotein levels (P > 0.05). The mRNA expression of Fra-1 was significantly lower in the ideal efficacy group than in the poor efficacy group (P < 0.05). Conclusions Fra-1 may be involved in the development of Wilms tumor and plays a certain role in its development, invasion and metastasis, but the mechanism remains to be further studied.
CHENG Yong-Feng,WANG Xue-Mei,YAN Mei et al. Expression of the Fra-1 gene in the peripheral blood of children with Wilms tumor[J]. CJCP, 2019, 21(2): 161-164.
CHENG Yong-Feng,WANG Xue-Mei,YAN Mei et al. Expression of the Fra-1 gene in the peripheral blood of children with Wilms tumor[J]. CJCP, 2019, 21(2): 161-164.
Verschuur AC, Vujanic GM, Van TH, et al. Stromal and epithelial predominant Wilms tumours have an excellent outcome:the SIOP 9301 experience[J]. Pediatr Blood Cancer, 2010, 55(2):233-238.
[4]
Gleason JM, Lorenzo AJ, Bowlin PR, et al. Innovations in the management of Wilms' tumor[J]. Ther Adv Urol, 2014, 6(4):165-176.
[5]
Zhong G, Chen X, Fang X, et al. Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway[J]. Oncol Rep, 2016, 35(1):447-453.
[6]
Iskit S, Schlicker A, Wessels L, et al. Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts diseasefree survival[J]. Oncotarget, 2015, 6(41):43146-43161.
[7]
Oliveira-Ferrer L, Kürschner M, Labitzky V, et al. Prognostic impact oftranscription factor Fra-1 in ER-positive breast cancer:contribution to a metastatic phenotype through modulation of tumor cell adhesive properties[J]. J Cancer Res Clin Oncol, 2015, 141(10):1715-1726.
[8]
Hasselblatt P, Gresh L, Kudo H, et al. The role of the transcription factor AP-1 in colitis-associated and β-catenindependent intestinal tumorigenesis in mice[J]. Oncogene, 2008, 27:6102-6109.
[9]
Kent LN, Rumi MAK, Kubota K, et al. FOSL1 is integral to establishing the maternal-fetal interface[J]. Mol Cell Biol, 2011, 31(23):4801-4813.
[10]
Lee BK, Uprety N, Jang YJ, et al. Fosl1 overexpression directly activates trophoblast-specific gene expression programs in embryonic stem cells[J]. Stem Cell Res, 2018, 26:95-102.
[11]
Desmet CJ, Gallenne T, Prieur A, et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis[J]. Proc Natl Acad Sci U S A, 2013, 110(13):5139-5144.
[12]
Sayan AE, Stanford R, Vickery R, et al. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL[J]. Oncogene, 2012, 31(12):1493-1503.
[13]
Kimura R, Ishikawa C, Rokkaku T, et al. Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosaromac cells[J]. Biochim Biophys Acta, 2011, 1813(8):1543-1553.
[14]
Zhang Q, Kleeberger SR, Reddy SP. DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung[J]. Am J Physiol Lung Cell Mol Physiol, 2004, 286(2):427-436.
[15]
Tam WL, Lu H, Buikhuisen J, et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells[J]. Cancer Cell, 2013, 24(3):347-364.
[16]
Logullo AF, Nonogaki S, Pasini FS, et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma[J]. Histopathology, 2011, 58(4):617-625.
[17]
Usui A, Hoshino I, Akutsu Y, et al. The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma[J]. Cancer, 2012, 118(13):3387-3396.
[18]
Wu J, Wu G, Lv L, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1[J]. Carcinogenesis, 2012, 33(3):519-528.
[19]
Zhong G, Chen X, Fang X, et al. Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway[J]. Oncol Rep, 2016, 35(1):447-453.
[20]
Verde P, Casalino LF, Yaniv M, et al. Deciphering AP-1 function in tumorigenesis:fra-ternizing on target promoters[J]. Cell Cycle, 2007, 6(21):2633-2639.
